Overview

Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and efficacy of a dose and dosage regimen of SBI-087 in seropositive patients with active Rheumatoid Arthritis, who are on a stable dose of methotrexate.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Collaborator:
Emergent Product Development Seattle LLC
Treatments:
Methotrexate